

CASE D0034 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Keith R. Lange
Type or print name

Signature

January 25, 2005
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1652

BOWEN ET AL.

Examiner: PROUTY, Rebecca E.

APPLICATION NO: 10/005,549

FILED: OCTOBER 29, 2001

FOR: POLYNUCLEOTIDE ENCODING AN ACTIVATED HUMAN T-
LYMPHOCYTE-DERIVED PROTEIN RELATED TO UBIQUITIN
CONJUGATING ENZYME

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

These references were cited in a search report in a corresponding European application. Copies of these references and the search report are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

01/31/2005 MAHRED1 00000019 193880 10005549

01 FC:1806 180.00 DA


Certificate under 37 C.F.R. §1.97(e)(1)

I, the undersigned attorney, hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.

Consideration of the Supplemental Disclosure Statement is respectfully requested. Please Charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$180.00 for filing of this Statement. An additional copy of this paper is enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-3883




Keith R. Lange
Attorney for Applicants
Reg. No. 44,201

Date: January 25, 2005

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0034 NP
APPLICATION NO.
10/005,549
APPLICANT
BOWEN ET AL.
FILING DATE
OCTOBER 29, 2001Group
1652

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	T. Maniatis, "A ubiquitin ligase complex essential for the NF-kB, Wnt/Wingless, and Hedgehog signaling pathways", GENES & DEVELOPMENT 13:505-510, March 1, 1999.
	AS	E. Schulze et al., "The maintenance of neuromuscular function requires UBC-25 in Caenorhabditis elegans", Biochemical and Biophysical Research Communications Vol. 305, no. 3, pp. 691-699, June 6, 2003.
	AT	Database Wormbase, Online "Gene summary for ubc-25", XP002300233; Database Accession No. WBGENE00006720.


EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.
D0034 NP
APPLICATION NO.
10/005,549
APPLICANT
BOWEN ET AL.
FILING DATE
OCTOBER 29, 2001Group
1652

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AA	DATABASE FLYBASE, Online "Synopsis of Gene CG2924" XP002300232; Database Accession No. CG2924. August 21, 2004.
AB	
AC	
AD	
AE	
AF	
AG	
AH	
AI	
AJ	
AK	
AL	
AM	
AN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.